Venn grabs German CRO, expands Euro footprint

Irish CRO Venn Life Sciences has agreed to trade nearly $1 million of stock for Germany's CRM Clinical Trials, a move that will stretch its reach into one of Europe's largest research markets. Venn expects CRM to add about $2 million in revenue for 2014, and the CRO said it's planning more M&A for the year. News

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

Genae's CEO says the transaction reflects recent focus on digital health and data-driven services.